Skip to main content
SpringerLink
Log in

Schwerpunkt triple-negatives Mammakarzinom

Die systemische Behandlung des triple-negativen Mammakarzinoms

  • schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Im Vergleich zu anderen Mammakarzinom-Subtypen ist die Prognose des triple-negativen Mammakarzinoms eher schlecht. Standardtherapie ist nach wie vor die Chemotherapie. Hoffnungen machen jetzt neuere Behandlungsansätze wie die PARP- oder Checkpointinhibiton.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Liedtke C et al. Response to neoadjuvant therapy and long-term survival in patients with TNBC. J Clin Oncol. 2008;26(8):1275–81

    Article  Google Scholar 

  2. von Minckwitz G et al. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol. 2012;30(15):1796–804

    Article  Google Scholar 

  3. Morante Z et al. Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer. SABCS. 2018;Abstr GS2-05

  4. Denkert C et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–91

    Article  CAS  Google Scholar 

  5. von Minckwitz G. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;(7):747-56

  6. Keaton Litton J et. al. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). J Clin Oncol. 2018;36(15_suppl):Abstr 508

    Article  Google Scholar 

  7. Keller AM et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22(19):3893–901

    Article  CAS  Google Scholar 

  8. Cortes J et al. EMBRACE Investigators: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914–23

    Article  CAS  Google Scholar 

  9. Tutt A et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018; 24(5):628–37

    Article  CAS  Google Scholar 

  10. Bardia A et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741–51

    Article  CAS  Google Scholar 

  11. Robson M et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523–33

    Article  CAS  Google Scholar 

  12. Litton JK et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753–63

    Article  CAS  Google Scholar 

  13. Schmid P et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. IMpassion 30 Trial. N Engl J Med. 2018;379(22):2108–21

    Article  CAS  Google Scholar 

  14. Vinayak S et al. TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. J Clin Oncol. 2018;36(15_suppl):Abstr 1011

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Onkologie und gynäkologisches Tumorzentrum, Universitätsspital Basel, Petersgraben 4, CH-4031, Basel, Schweiz

    Julia Landin &  Marcus Vetter

Authors
  1. Julia Landin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcus Vetter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus Vetter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Landin, J., Vetter, M. Die systemische Behandlung des triple-negativen Mammakarzinoms. Info Onkol. 22, 24–27 (2019). https://doi.org/10.1007/s15004-019-6471-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6471-7

Search

Navigation